Coherus Oncology Inc (CHRS)

EBITDA Margin

-291.46%

TTM · Period ending:

CHRS logo

CHRS EBITDA Margin

Latest reported-291.46%
CHRS TTM EBITDA Margin (-1784.44% → -291.46%)
High-resolution chart · PNG

CHRS ebitda margin history

Trailing twelve months (TTM). Each value covers four complete reported quarters.

Coherus Oncology Inc EBITDA Margin — Trailing twelve months (TTM)
Period endingEBITDA Margin
-291.4599%
-340.9871%
-403.5829%
-204.9995%
-93.8062%
-50.0056%
-61.3761%
-61.6861%
-71.4015%
-84.6625%
-75.3911%
-82.6273%
-122.9409%
-127.7799%
-121.1043%
-102.7575%
-72.2108%
-59.281%
-79.65%
-56.1938%
-34.9654%
-10.8957%
33.5754%
38.6906%
42.6823%
39.0017%
31.7569%
2.8934%
-84.6919%
-459.8981%
-13,959.8566%
-14,482.5835%
-10,516%
-66.2826%
-67.4944%
-58.9839%
-45.4116%
-567.252%
-667.6934%
-736.5967%
-740.6136%
-374.643%
-291.4166%
-253.3466%
-251.4877%
-744.3053%
-1,062.4893%
-1,784.442%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.